Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$7.04 USD
+0.25 (3.68%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.04 USD
+0.25 (3.68%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $7.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth F Momentum C VGM
Zacks News
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising
by Zacks Equity Research
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
by Zacks Equity Research
FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
Can Ironwood (IRWD) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session
by Zacks Equity Research
Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
5 High Earnings Yield Stocks to Add to Your Portfolio
by Rimmi Singhi
Earnings yield can be more illuminating than the traditional P/E ratio as the former facilitates comparison of stocks with fixed-income securities.
Ironwood (IRWD) Q3 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the third quarter.
Ironwood Pharmaceuticals (IRWD) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 64.29% and 10.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharma's Xywav Succeeds in Idiopathic Hypersomnia Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares rise.
Ironwood to End IW-3718 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, IW-3718, fails to meet primary endpoint in a phase III study evaluating it in patients with refractory GERD.
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up
by Zacks Equity Research
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
Pacira (PCRX) Gains Positive CHMP Opinion for Exparel in EU
by Zacks Equity Research
The CHMP gives a positive opinion recommending an approval for Pacira's (PCRX) Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.
Why Is Ironwood (IRWD) Down 3.1% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surging Earnings Estimates Signal Upside for Ironwood (IRWD) Stock
by Zacks Equity Research
Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Ironwood (IRWD) Q2 Earnings Beat on Solid Linzess Sales
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. COVID-19 impacts enrollment in clinical studies.
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 100.00% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Next Week: What You Should Expect
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Ironwood (IRWD) Down 3.6% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Ironwood to Halt MD-7246 Development After Study Failure
by Zacks Equity Research
Ironwood's (IRWD) pipeline candidate, MD-7246 fails to meet primary endpoint in a phase II study evaluating it in patients with irritable bowel syndrome with diarrhea.
Ironwood (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. COVID-19 impacts enrollment in clinical studies.
Ironwood Pharmaceuticals (IRWD) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -63.64% and -7.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.